Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: A 3-year prospective observational study

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 4, 2004, Pages 435-442

  Green, J R B ^a   Swan, C H J ^a   Gibson, J A ^b   Kerr, G D ^c   Swarbrick, E T ^d   Thornton, P C ^e  

^a CITY GENERAL HOSPITAL   (United Kingdom)

^b STAFFORDSHIRE GENERAL HOSPITAL   (United Kingdom)

^c ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^d NEW CROSS HOSPITAL   (United Kingdom)

^e Biorex Laboratories Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ANGINA PECTORIS; ARTERY EMBOLISM; ARTICLE; ASTHMA; BACKACHE; BREAST TUMOR; CELLULITIS; CHOLELITHIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENTEROBACTER INFECTION; FATIGUE; FEASIBILITY STUDY; FEMALE; FLATULENCE; HEADACHE; HEART INFARCTION; HUMAN; HYPOMANIA; LABORATORY TEST; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; PSORIASIS; PUSTULE; RASH; REMISSION; RESPIRATORY TRACT INFECTION; SEPTIC SHOCK; SIDE EFFECT; SYMPTOMATOLOGY; THYROTOXICOSIS; ULCERATIVE COLITIS; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOSALICYLIC ACIDS; COHORT STUDIES; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PATIENT PARTICIPATION; PHENYLHYDRAZINES; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 1542329562     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01866.x     Document Type: Article

References (15)

1. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
2. British Society of Gastroenterology. Inflammatory Bowel Disease. Guidelines in Gastroenterology, September 1996. Online at: http://www.bsg.org. uk/pdf_word_docs/ibd.pdf. Date accessed 4 December 2002.
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997; 92: 204-11.
4. Robinson JA, Wilkin D, Thompson DG, Roberts C. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001; 358: 976-81.
5. Green JRB, Swan CHJ, Rowlinson AE, et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5ASA-releasing agent, balsalazide. Gastroenterology 1992; 102: A631(Abstract).
6. Green JRB, Lobo AJ, Holdsworth CD, et al. and the ABACUS Investigator Group. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998; 114: 15-22.
7. Green JRB, Swan CHJ, Rowlinson AE, et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology 1993; 104: A709(Abstract).
8. Mansfield JC, Giaffer MH, Cann PA, et al. Is high dose balsalazide better than sulphasalazine in initial management of ulcerative colitis? Gut 1991; 32: A1217(Abstract).
9. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988; 2: 237-43.
10. Giaffer MH, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 1992; 6: 479-85.
11. Green JRB, Swan CHJ, Rowlinson A, et al. Short report comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992; 6: 647-52.
12. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001; 49: 783-9.
13. Green JRB, Gibson JA, Kerr GD, et al. and the ABACUS Investigator Group. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment Pharmacol Ther 1998; 12: 1207-16.
14. Meyers S, Janowitz HD. The 'natural history' of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol 1989; 11: 33-7.
15. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992; 6: 51-9.